27 May 2022
Special software has been developed at the South Urals State University (SUSU) in the city of Chelyabinsk. It helps determine if a drug candidate does really hit (and positively impact) a target in human cells to be treated. Pharmaceutical companies may “soon” expect to get access to the new product.
Dr. Maria Grishina of SUSU’s Drug Computer Modeling Research Lab explained that to develop the software, her team had used as initial inputs what’s known in science as electronic ligand density maps.
Ligands are chemical compounds that create bonds with cell receptors, thus providing pharmacological effect. Ligand maps show concentrations of contact zones which helps assess how efficiently a drug interacts with cell receptors in the human body.
Quantum-chemical methods have been applied to produce the maps.
The software has been reportedly tested when the team successfully identified the zones of contact between coronavirus (SARS-CoV-2) complexes and the ligand of favipiravir-RTP, a drug believed to be effective against viral infections.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024